OSI Pharmaceuticals, Inc.

CORRECTING AND REPLACING Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer

Published in Cancer Weekly, June 2nd, 2009

Eighth graph, third sentence should read: Fifty-five percent of patients in the Tarceva arm and 64% of patients on placebo received subsequent therapy after progressing. (sted Sixty-four percent of patients in the Tarceva arm and 55% of patients on placebo received subsequent therapy after progressing.)

The corrected release reads: DATA FROM THE PHASE III SATURN STUDY SHOW TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL WHEN USED AS A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER -- Data Showed Tarceva Improved PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma -- Patients with an EGFR Mutation Achieved a 10 Fold...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2009-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry